Dr. Peter Meintjes served as a Chief Commercial Officer at Transplant Genomics, Inc., since April 2020. he serves as CEO at Pacific Edge Limited since January 17, 2022. He was responsible for leding the co...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Peter Meintjes	Chief Executive Officer	3yrs	Veri yok	0.081% NZ$ 38.7k
Grant Gibson	Chief Financial Officer	5.1yrs	Veri yok	0.020% NZ$ 9.7k
Darrell Morgan	Chief Operating Officer	2.3yrs	Veri yok	Veri yok
Justin Harvey	Chief Technology Officer	5yrs	Veri yok	Veri yok
Parry Guilford	Chief Scientific Officer & Member of Scientific Advisory Board	no data	NZ$134.00k	Veri yok
Andrew McIntosh	Chief Digital Officer	3.6yrs	Veri yok	Veri yok
Glen Costin	President of Asia Pacific	no data	Veri yok	Veri yok
Tamer Aboushwareb	Chief Medical Officer	no data	Veri yok	Veri yok
David Levison	Executive Chairman & President of Pacific Edge Diagnostics USA	no data	NZ$53.00k	Veri yok

3.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: PEB 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Parry Guilford	Chief Scientific Officer & Member of Scientific Advisory Board	no data	NZ$134.00k	Veri yok
David Levison	Executive Chairman & President of Pacific Edge Diagnostics USA	no data	NZ$53.00k	Veri yok
R. Spence	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Chris Gallaher	Independent Non-Executive Chairman of the Board	8.5yrs	NZ$115.00k	0.12% NZ$ 59.0k
Osamu Ogawa	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Bryan Raymond Williams	Member of Scientific Advisory Board & Independent Deputy Non-Executive Chairman	11.6yrs	NZ$70.00k	0.075% NZ$ 36.0k
Michael Sullivan	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Nikola Kasabov	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Murray Brennan	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Anatole G. Masfen	Independent Non-Executive Director	16.8yrs	NZ$60.00k	1.15% NZ$ 549.9k
Anna Stove	Independent Non-Executive Director	3.8yrs	NZ$65.00k	0.00062% NZ$ 297.0
Sarah Park	Independent Non-Executive Director	6.1yrs	NZ$70.00k	0.0072% NZ$ 3.5k

8.5yrs

Ortalama Görev Süresi

75yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PEB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/21 01:06
Gün Sonu Hisse Fiyatı	2025/01/21 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Pacific Edge Limited 9 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Anubhav Saxena	Bell Potter
null null	Brookline Capital Markets
Gregory Main	Credit Suisse

Pacific Edge Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Pacific Edge Limited, Annual General Meeting, Sep 24, 2024

Insufficient new directors

Pacific Edge Limited Announces Board Changes

Independent Non-Executive Director recently bought NZ$3.1m worth of stock

Key Executive recently bought NZ$54k worth of stock

Pacific Edge Limited Appoints Darrell Morgan as Chief Operating Officer

Recent updates

Price target decreased by 23% to NZ$0.12

New minor risk - Profitability

It's Down 26% But Pacific Edge Limited (NZSE:PEB) Could Be Riskier Than It Looks

First half 2025 earnings released: NZ$0.018 loss per share (vs NZ$0.019 loss in 1H 2024)

Is Pacific Edge (NZSE:PEB) In A Good Position To Invest In Growth?

Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024

Price target increased by 19% to NZ$0.15

New major risk - Share price stability

Further Upside For Pacific Edge Limited (NZSE:PEB) Shares Could Introduce Price Risks After 33% Bounce

Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation

Full year 2024 earnings released: NZ$0.036 loss per share (vs NZ$0.033 loss in FY 2023)

No longer forecast to breakeven

Pacific Edge Limited, Annual General Meeting, Sep 24, 2024

Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024

Investors Holding Back On Pacific Edge Limited (NZSE:PEB)

Insufficient new directors

Pacific Edge Limited Announces Board Changes

Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation

Lacklustre Performance Is Driving Pacific Edge Limited's (NZSE:PEB) 30% Price Drop

Consensus EPS estimates upgraded to NZ$0.034 loss

First half 2024 earnings released: NZ$0.019 loss per share (vs NZ$0.013 loss in 1H 2023)

Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023

Price target decreased by 7.8% to NZ$0.15

Independent Non-Executive Director recently bought NZ$3.1m worth of stock

Key Executive recently bought NZ$54k worth of stock

Price target decreased by 34% to NZ$0.38

Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023

Fewer Investors Than Expected Jumping On Pacific Edge Limited (NZSE:PEB)

Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Pacific Edge Announces the Acceptance for Publication of New Clinical Evidence That Shows Significant Improvements in the Performance of its Genomic Diagnostic Cxbladder Tests

Consensus forecasts updated

First half 2023 earnings released: NZ$0.013 loss per share (vs NZ$0.012 loss in 1H 2022)

Price target decreased to NZ$0.61

Companies Like Pacific Edge (NZSE:PEB) Are In A Position To Invest In Growth

Price target decreased to NZ$0.72

Pacific Edge Limited Appoints Darrell Morgan as Chief Operating Officer

Pacific Edge Limited to Report First Half, 2023 Results on Nov 26, 2022

Consensus revenue estimates fall by 27%

Pacific Edge (NZSE:PEB) Is In A Good Position To Deliver On Growth Plans

Now 26% undervalued after recent price drop

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to NZ$1.11

Pacific Edge Limited Announces It Is Advancing Its Clinical Evidence Generation Program with Lobster

Insufficient new directors

Consensus forecasts updated

Price target decreased to NZ$1.32

Pacific Edge (NZSE:PEB) Is In A Strong Position To Grow Its Business

Insufficient new directors

Consensus revenue estimates fall to NZ$12.9m

First half 2022 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

CEO, MD & Executive Director exercised options to buy NZ$478k worth of stock.

Consensus EPS estimates fall to -NZ$0.014

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Full year 2021 earnings released: NZ$0.02 loss per share (vs NZ$0.032 loss in FY 2020)

Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?

Insider recently sold NZ$130k worth of stock

Don't Ignore The Fact That This Insider Just Sold Some Shares In Pacific Edge Limited (NZSE:PEB)

Insider recently sold NZ$120k worth of stock

Did The Underlying Business Drive Pacific Edge's (NZSE:PEB) Lovely 750% Share Price Gain?

Have Insiders Been Selling Pacific Edge Limited (NZSE:PEB) Shares?

Analysts update estimates

Pacific Edge Limited's (NZSE:PEB) Profit Outlook

Pacific Edge Limited, Annual General Meeting, Jul 29, 2021

Pacific Edge Limited to Report First Half, 2022 Results on Nov 26, 2021